Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tylenol labeling clarification

This article was originally published in The Tan Sheet

Executive Summary

McNeil has changed labeling on Children's TylenolMeltaways blister packs to "80 mg per tablet" from "medicine per dose 80 mg" to prevent consumer confusion, according to the firm. Current individual blister packs containing either one or two 80 mg tablets both state "Children's Tylenol 80 mg," which could lead users to mistakenly assume both tablets are needed for an 80 mg dose, the Institute for Safe Medication Practices states in a recent newsletter. McNeil changed the blister-pack labeling upon learning of the potential confusion, even though no misdosing has occurred since the label's introduction in 2000, the firm notes. FDA deemed a recall unnecessary, but the company is in the process of printing new blister-pack labeling and will begin replacing products promptly, McNeil says...

You may also be interested in...



Tylenol Meltaways, Soft Chews Recalled Due To Potential Dosing Errors

McNeil Consumer & Specialty Pharmaceuticals is manufacturing and shipping Children's Tylenol Meltaways with revised labeling that more clearly communicates the dose of acetaminophen in each tablet

Vaccine Company CEOs Face Supply Probe In EU

AstraZeneca's CEO and other leaders from COVID-19 vaccine companies will face some tough questions in Brussels, but the European Commission wants to put differences behind it and solve the vaccine supply problem as soon as possible.

Trial Shows Lateral Flow Antibody Testing Could Be Used To Assess COVID-19 Vaccine Efficacy

Abingdon Health has announced that a study run in conjunction with the UK Rapid Test Consortium has demonstrated that its AbC-19 test could be an effective tool for testing vaccine efficacy. 

Topics

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel